Violette Shelia M. sold $8K of QTTB

Violette Shelia M. (Chief Scientific Officer) sold 917 shares of Q32 Bio Inc. (QTTB) at $8.32 on 2026-10-06.

Original reporting
SEC EDGAR · Violette Shelia M.
Published Oct 14, 2026, 9:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 14, 2026, 9:31 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$QTTB
Bearish
high confidence
Mentioned
$QTTB
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$QTTBBearishLow
01

Why it matters

While the dollar amount is trivial, the sale by a senior scientific officer may be interpreted by investors as a mild negative signal.

02

Market read

The filing is a routine insider transaction with limited trading relevance; most traders will likely ignore it.

03

What to watch

Potential upcoming corporate events (e.g., trial data) that may have prompted the insider to liquidate a small position.

Relevance 3/10Novelty 3/10Timing: post‑market filing today

Background

Form 4 filings provide the first public disclosure of insider transactions, offering transparency into insider sentiment.

Company-level read

Ticker impact

$QTTBBearishHigh confidence
Context

Chief Scientific Officer sold 917 shares for $7,629, a routine insider sale disclosed via Form 4.

Expected impact

modest downward pressure as market prices in the insider sale

Evidence & confidence

Small transaction size relative to float and low dollar amount suggests limited market impact, but sells by senior insiders are often viewed negatively.

Market effects

Minimal; biotech sector unlikely to be affected by a single small insider sale.

None; the filing is U.S. specific and does not influence broader regional markets.

Insignificant; no global market impact expected.

Counterpoint

The sale could be a routine portfolio rebalancing and not indicative of negative fundamentals.

Key entities

  • Q32 Bio Inc.

    Biotech firm developing RNA‑based therapeutics, ticker QTTB.

  • Violette Shelia M.

    Chief Scientific Officer of Q32 Bio who executed the sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$QTTBMedAI 8/10

Q32 Bio Reports Q3 Results; Advances Bempikibart Toward Phase 3 In Alopecia Areata

Q32 Bio (QTTB) reported Q3 2026 results, with R&D expenses rising to $5.1M and net loss increasing to $8.9M. The company presented Phase 2a trial data for bempikibart, showing a 35.3% mean reduction in SALT scores for alopecia areata patients. Q32 Bio plans to initiate a Phase 3 trial in early 2027 and has $289.6M in cash reserves. The stock is currently trading at $8.81, up 0.57%.

$QTTBLow

Q32 Bio 3Q 2026: Net loss $8.9M, EPS $(0.26) — 10-Q Summary

Q32 Bio reported a Q3 2026 net loss of $8.9M, up 20.7% YoY, with EPS loss narrowing to $0.26. The company's bempikibart study showed improved SALT scores and no serious adverse events. Q32 plans regulatory discussions in Q4 2026 and aims to advance bempikibart in early 2027. Akebia will develop ADX-097 after the asset sale.

$QTTBMedAI 8/10

Q32 Bio Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Q32 Bio reported Q3 2026 results, highlighting positive SIGNAL-AA clinical trial data for bempikibart, a treatment for alopecia areata. The company presented 36-week results and 16-week off-drug findings at EADV Congress, showing durable responses. Q32 Bio plans to initiate a registration-directed program in 1H 2027 and has $289.6M in cash. The company also strengthened its leadership team and expects Phase 3 topline results from the planned program.